Novo Nordisk A/S (NOVOb.CO): WeGovy franchise TRx tracker (w/e 17th Jul). Strong rebound in 2nd full week of Medicare coverage.

Research evidence excerpt

Novo Nordisk A/S (NOVOb.CO): WeGovy franchise TRx tracker (w/e 17th Jul). Strong rebound in 2nd full week of Medicare coverage.

Novo Nordisk A/S (NOVOb.CO)

24 July 2026 Citi Research

Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning

of the Indonesian capital market laws and regulations.

The Product is made available in Japan by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial

Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock

Exchange and Osaka Securities Exchange. Otemachi Park Building, 1-1-1 Otemachi, Chiyoda-ku, Tokyo 100-8132 Japan. In the

event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If

you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help.

The product is made available in the Kingdom of Saudi Arabia in accordance with Saudi laws through Citigroup Saudi Arabia,

which is regulated by the Capital Market Authority (CMA) under CMA license (17184-31). 2239 Al Urubah Rd – Al Olaya Dist.

Unit No. 18, Riyadh 12214 – 9597, Kingdom Of Saudi Arabia.

The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd. (CGMK), which is regulated by the

Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). The

address of CGMK is Citibank Center, 50 Saemunan-ro, Jongno-gu, Seoul 03184, Korea. KOFIA makes available registration

information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration

information on research analysts of

CGMK.